TG1101-RMS404 - A Post-Authorization Study to Characterize the Safety of BRIUMVI (ublituximab) Use in Pregnant Patients with Multiple Sclerosis Using Data from a US Administrative Healthcare Claims Database

05/06/2025
07/10/2025
EU PAS number:
EUPAS1000000612
Study
Ongoing
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

TG1101-RMS404 V1.0 Draft 4 in EMA.pdf

English (876.13 KB - PDF) View document
Updated protocol

tg1101-rms404-protocol-v2.0_10Jul2025.pdf

First published: 06/10/2025
English (813.66 KB - PDF) View document

tg1101-rms404-protocol-v2.0_10Jul2025.pdf

First published: 06/10/2025
English (813.66 KB - PDF) View document
Study results
Study report
Other information